Jeffrey Balzer, PhD

Associate Professor of Neurological Surgery, Neuroscience & Acute and Tertiary Care Nursing
Director of Clinical Services, Center for Clinical Neurophysiology
Director of Cerebral Blood Flow Laboratory

Jeffrey Balzer




Jeffrey Balzer, PhD, is associate director for clinical services and staff clinical neurophysiologist at the Center for Clinical Neurophysiology and director of the Cerebral Blood Flow Laboratory at the University of Pittsburgh Medical Center.

His current research interests range from the utilization of genetic biomarkers for the prediction of delayed cerebral ischemia in subarachnoid hemorrhage to the use of blood flow measures in mild head injury and concussion to vagal nerve stimulation to control cardiac arythmias. Dr. Balzer received his undergraduate education at the University of Pittsburgh, where he also pursued a graduate education and a PhD in behavioral neuroscience.

Dr. Balzer is also the secretary/treasurer of the American Board of Neurophysiological Monitoring.

He has published 45 refereed articles and 11 book chapters.

Dr. Balzer's publications can be reviewed through the National Library of Medicine's publication database.

Specialized Areas of Interest

Intraoperative neurophysiological monitoring; concussion, cerebral blood flow.

Board Certifications

American Board of Neurophysiological Monitoring

Hospital Privileges

Children’s Hospital of Pittsburgh of UPMC
Jameson Hospital
Magee-Womens Hospital of UPMC
Monongahela Valley Hospital
Shriner’s Hospital
UPMC Hamot
UPMC Horizon
UPMC McKeesport
UPMC Mercy
UPMC Passavant
UPMC Presbyterian
UPMC St. Margaret’s
UPMC Shadyside

Professional Organization Membership

American Clinical Neurophysiology Society
American Association for the Advancement of Science
American Society for Neurophysiological Monitoring (Fellow)
New York Academy of Sciences
Pittsburgh Neuroscience Society

Research Activities

Dr. Balzer’s main clinical research over the past year focused on characterizing the development of delayed cerebral ischemia in the SAH. He has been able to identify several key genetic biomarkers and evaluate how their concentrations change after SAH as well as to characterize how cerebral perfusion pressure influences long-term outcomes in this patient population. He has also characterized how the use of a non-invasive bedside monitor, namely cerebral oximetry, correlates with delayed cerebral ischemia.

In addition to Dr. Balzer’s clinical research in the SAH patient population, he has also begun to extensively characterize the utility of SSEP and MEP in prognosis in the severe TBI patient population. He also just received a Copeland grant to use the same diagnostic technology in the ICU to serially test SAH patients in an attempt to characterize changes in their neurological status as well as predict outcomes. He is also involved in early clinical trials in humans evaluating the use of transvenous stimulation of the vagus nerve to treat cardiac arythmias.

Dr. Balzer also has begun a series of studies investigating the effects of various degrees of spinal cord injury on SSEP and MEP recordings in the acute and chronic phases in rats. He would like to use this animal model as a means by which to characterize and predict how changes in intraoperative monitoring data in patients undergoing spinal procedures will ultimately translate to transient and permanent clinical deficits.